Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Q1 2018 Earnings Conference Call - Preliminary Transcript
May 08, 2018 • 08:30 am ET
Thank you for joining the Intercept Pharmaceuticals first quarter 2018 financial results conference call. All participants are now in a listen only mode. Following opening remarks intercepts management will open the lines for a question and answer period. Please be advised that this call is being recorded at the company's request and a webcast of this call will be archived on the company's website for two weeks from today's date. I would now like to introduce Dr. Mark Vignola Intercepts Executive Director of Corporate development and Investor Relations. Please go ahead.
Dr. Mark Vignola
Good morning and thank you for joining us on today's call. This morning we issued a press release announcing our first quarter 2018 financial results which is available on our website at www.interceptpharma.com Before we begin our discussion, I'd like to note that during our call in question and answer session today, we're going to be certain forward looking statements. Including statements regarding the progress, timing and results of our clinical trials, including our clinical trials for the treatment of Nash, the safety and efficacy of our approved product or caliber, the potential approval of OCA and indications other than PDC the timing and potential commercial success of both ca and other product candidates we may develop and our strategy future operations future financial position, future revenue, projected costs, prospects, plans, objectives and management and expected market growth. listeners are cautioned not to place undue reliance on these forward looking statements, which speak only as of the date of this call, and we undertake no obligation update any forward looking statement, except as required by law.
These forward looking statements are based on estimates and assumptions by our management that, although believed to be reasonable, are inherently uncertain subject to a number of risks and uncertainties. Some but not necessarily all of the factors that could cause our actual results to differ materially from our historical results are those anticipated or predicted by our forward looking statements are discussed in this morning's press release in our periodic filings with the US securities exchange commission, including our annual report on form 10 k for the year ended December 31, 2017. In addition, please note that LCA is an investigational product that has not been approved for use by any regulatory authority, any indication of the primary biliary cholangitis or PBC. No conclusions can be drawn concerning the safety or efficacy of OCA and other indications at this time. Today's call will begin remarks from our CEO Dr. Mark Pruzanski, followed by those from our president, US Commercial and strategic marketing Richard Kim, our president International, Lisa bright, and our Chief Financial Officer Sandip Kapadia will then open the call to take your questions. Let me now turn the call over to our CEO Dr. Mark Pruzanski.
Dr. Mark Pruzanski
Thanks, Mark. Good morning, everyone. And thank you for joining us on today's call. We accomplished a great deal in the first quarter of this year and are making good progress against the goals we've